Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 619 checkpoint-related abstracts that have been carefully screened and added to the Beacon database. Of these 619 abstracts, 612 presented clinical trial data, and the remaining 7 presented preclinical data.
The most common ICM target asset presented at ASCO 2022 was PD-1 with a total of 488 abstracts (484 clinical and 4 preclinical). Within disease indication, lung cancer and skin cancer are the most studied solid tumors at ASCO with a total of 150 abstracts. And within blood cancer indications, lymphoma and leukemia are amongst the most studied blood cancers with a total of 17 abstracts.
For more insight please download the sample, contact us, or request a demo.
Find out more
This insight and data is part of the subscription to Beacon Checkpoint.
Speak with our Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your checkpoint questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements